この記事を読む

輸血の既往が予後を変える?

Prognostic impact of blood transfusion in patients with metastatic non-small cell lung cancer receiving chemotherapy. Sa…

この記事を読む

アファチニブのlast resort

First-line afatinib for advanced EGFRm+ NSCLC: Analysis of long-term responders in the LUX-Lung 3, 6, and 7 trials. Schu…

この記事を読む

ICIにおける脳転移の予後

Outcome of Patients with Non-Small Cell Lung Cancer and Brain Metastases Treated with Checkpoint Inhibitors. Hendriks LE…

この記事を読む

EGFR-TKIへの耐性機序としてのBRAF rearrangements

Acquired BRAF Rearrangements Induce Secondary Resistance to EGFR therapy in EGFR-Mutated Lung Cancers. Vojnic M et al. J…

この記事を読む

KRAS陽性に対する免疫治療

Efficacy of Immune Checkpoint Inhibitors in KRAS-Mutant Non-Small Cell Lung Cancer (NSCLC). Jeanson A et al. J Thorac On…

この記事を読む

免疫チェックポイント阻害薬の後、すぐにオシメルチニブは危険

Severe immune-related adverse events are common with sequential PD-(L)1 blockade and osimertinib. Schoenfeld AJ et al. A…

この記事を読む

抗生物質投与と免疫療法

Association between antibiotic-immunotherapy exposure ratio and outcome in metastatic non small cell lung cancer. Galli …

この記事を読む

肺のリンパ腫の診断、浸潤影が多く画像では難しい

Clinical features and outcomes of pulmonary lymphoma: A single center experience of 180 cases. Zhang MC et al. Lung Canc…

この記事を読む

高齢者に対するペメトレキセド+ベバシズマブ。思ったほど縮小しない?

Randomized phase II study of Pemetrexed or Pemetrexed plus bevacizumab for elderly patients with previously untreated no…

この記事を読む

オリゴメタへの局所療法の追加は予後を改善する

Local Consolidative Therapy Vs. Maintenance Therapy or Observation for Patients With Oligometastatic Non-Small-Cell Lung…